Dr. Jahanzeb on the APHINITY and ExteNET Trials in Breast Cancer
Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the APHINITY and ExteNET studies in breast cancer.
Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the APHINITY and ExteNET studies in breast cancer.
The APHINITY study investigated the dual HER2 blockade of pertuzumab (Perjeta) and trastuzumab (Herceptin) plus chemotherapy. In the metastatic setting, there was data showing these 2 antibodies result in some additional toxicities, however, they have not been shown to cause much incremental cardiotoxicity, Jahanzeb explains.
The trial completed accrual in August of 2013, and while results are expected this year, they are not yet available. However, Jahanzeb says, it has been announced that the results are positive.
Five-year data for the ExteNET study, which investigated neratinib following trastuzumab, also looks positive, similar to the previously reported 2-year and 3-year data, Jahanzeb says.
<<<
